Orvosi Hetilap 2013-09-29

[Drug therapy for acromegaly].

Miklós Góth

Index: Orv. Hetil. 154(39) , 1527-34, (2013)

Full Text: HTML

Abstract

Prolonged overproduction of growth hormone, like insulin-like growth factor-1 hypersecretion leads to acromegaly in adults. This is associated with several co-morbidities and increased mortality. Despite typical clinical features and modern diagnostic tools, it often takes years to diagnose from the onset of the disease. The aims of the treatment are to reduce or control tumour growth, inhibit growth hormone hypersecretion, normalize insulin-like growth factor-1 levels, treat co-morbidities and, therefore, reduce mortality. There are three approaches for therapy: surgery, medical management (dopamine agonists, somatostatin analogues and growth hormone receptor antagonist), and radiotherapy. Efficient therapy of the disease is based on the appropriate multidisciplinary team management. The review provides a summary of medical treatment for acromegaly.

Related Compounds

  • CB-154 mesylate
  • Lanreotide acetate
  • Octreotide acetate
  • Cabergoline

Related Articles:

Dopamine-2 receptor activation suppresses PACAP expression in gonadotrophs.

2014-07-01

[Endocrinology 155(7) , 2647-57, (2014)]

Does bromocriptine play a role in decreasing oxidative stress for early weaned programmed obesity?

2014-01-24

[Life Sci. 95(1) , 14-21, (2014)]

Mediation of dopamine D2 receptors activation in post-conditioning-attenuated cardiomyocyte apoptosis

2014-04-15

[Exp. Cell Res. 323(1) , 118-30, (2014)]

Combined low calcium and lack magnesium is a risk factor for motor deficit in mice.

2013-01-01

[Biosci. Biotechnol. Biochem. 77(2) , 266-70, (2013)]

Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects.

2012-10-01

[J. Am. Heart Assoc. 1(5) , e002279, (2012)]

More Articles...